Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mallinckrodt has announced that it was granted a patent from the US Patent and Trademark Office which contains composition claims directed to unique design, formulation, pharmacokinetic, and release characteristics of Xartemis XR.
Subscribe to our email newsletter
Xartemis XR (formerly known as MNK-795) is an investigational extended-release oral formulation of oxycodone and acetaminophen that has been studied with twice daily dosing for the management of acute pain in a post-surgical model.
If approved, Xartemis XR will be the first oxycodone and acetaminophen combination medication specifically designed with immediate- and extended-release components. The patent, US Patent Number 8,658,631, was issued on 25 February 2014.
The release profile of Xartemis XR combines Mallinckrodt-proprietary technology and Depomed’s advanced Acuform drug delivery technology. Between the Mallinckrodt and Depomed patent families, Mallinckrodt believes Xartemis XR will have strong patent protection for its novel features.
Mallinckrodt president and CEO Mark Trudeau noted Xartemis XR, a key driver in the company’s near-term pipeline, represents an important component of its strategy to unlock continued potential and grow its branded specialty pharmaceutical portfolio.
"Mallinckrodt’s patent, which includes the product’s release profile, underscores our ability to effectively leverage our core formulation capabilities and partnerships," Trudeau added.
Acuform is a registered trademark of Depomed.